Publications by authors named "A Jauregui-Amezaga"
Background And Aims: Mucosal healing is considered as a key therapeutic endpoint in inflammatory bowel diseases (IBD) and comprises endoscopic improvement of inflammation without taking barrier healing into account. Mucins are critical components of the mucosal barrier function that give rise to structurally diverse isoforms. Unraveling disease-associated mucin isoforms that could act as an indication for barrier function would greatly enhance IBD management.
View Article and Find Full Text PDFThe management of patients with inflammatory bowel disease (IBD) aims to control inflammation through the use of immunosuppressive treatments that target various points in the inflammatory cascade. However, the efficacy of these therapies in the long term is limited, and they often are associated with severe side effects. Although the pathophysiology of the disease is not completely understood, IBD is regarded as a multifactorial disease that occurs due to an inappropriate immune response in genetically susceptible individuals.
View Article and Find Full Text PDFBackground: Data regarding the clinical outcome of patients with immune checkpoint inhibitor (ICI)-induced colitis are scant. We aimed to describe the 12-month clinical outcome of patients with ICI-induced colitis.
Materials And Methods: This was a retrospective, European, multicentre study.
Background: Data on ustekinumab and vedolizumab in the elderly inflammatory bowel disease (IBD) population are limited. The aim of the current study was to assess the safety and effectiveness of both in an elderly real-life population.
Methods: A multicentric retrospective study was performed on IBD patients who started vedolizumab or ustekinumab between 2010 and 2020.
Article Synopsis
- The study aimed to evaluate the effectiveness of early medical prophylaxis versus waiting for endoscopy findings in preventing postoperative recurrence (POR) in patients with Crohn's disease after ileocaecal resection (ICR).
- Out of 346 patients, those receiving early prophylactic treatment (Cohort 1) had significantly lower endoscopic recurrence rates compared to those who only received treatment based on endoscopy results (Cohort 2).
- While both groups did not show significant differences in severe endoscopic POR or time to surgical recurrence, the proactive group had a lower treatment burden when using immunomodulators.